^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    JAMA Oncol
    Title:

    Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

    Published date:
    04/09/2020
    Excerpt:
    As of June 1, 2017, the objective response rate among patients with PD-L1 TC ≥25% was 35.6%, 34.4%, and 37.7% with durvalumab, durvalumab plus tremelimumab, and chemotherapy, respectively (eTable 7 in Supplement 1).
    DOI:
    10.1001/jamaoncol.2020.0237
    Trial ID:
    MYSTIC
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Ann Oncol
    Title:

    ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer?

    Published date:
    03/24/2020
    Excerpt:
    In heavily pretreated patients with mNSCLC, durvalumab demonstrated clinically meaningful improvements in OS and PFS versus SoC (patients with PD-L1 TC ≥25%); numerical improvements in OS and PFS for durvalumab + tremelimumab versus SoC were observed (patients with PD-L1 TC <25%).
    DOI:
    https://doi.org/10.1016/j.annonc.2020.02.006
    Trial ID:
    ARCTIC
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase II Study: Second line therapy in patients with non small cell lung cancer (NSCLC) with Durvalumab plus Tremelimumab after platinum based chemotherapie compared with platinum based chemotherapy alone Phase II Studie: Zweitlinientherapie in Patienten mit nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Durvalumab plus Tremelimumab nach Platinum-basierter Chemotherapie verglichen mit alleiniger Platinum-basierter Chemotherapie

    Excerpt:
    ...Documented tumor PD-L1 expression status of ≥50%. ...
    Trial ID:
    2017-003780-35
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

    Excerpt:
    ......
    Trial ID:
    NCT04499053
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

    Excerpt:
    ......
    Trial ID:
    NCT02888743